Comparing two different doses of Atorvastatin for decrease the level of LDL in ACS patient.

Comparing two different doses of Atorvastatin for decrease the level of LDL in ACS patient and determinate the effective dose of drug.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20140921019240N4

Enrollment

Registered

2018-06-08

Start date

2018-06-22

Completion date

Unknown

Last updated

2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute coronary syndrome. Acute ischemic heart disease, unspecified

Interventions

Intervention 1: Intervention group: The intervention group received three months of treatment with 40 mg of atorvastatin daily from the start of study. Atorvastatin product by Abidi Pharmaceutical Com

Eligibility

Sex/Gender

All

Age

No minimum to 75 Years

Inclusion criteria

Inclusion criteria: ?ACS (acute coronary syndrom) patients who are admit in CCU (coronary care unit) in Heshmatie hospital

Exclusion criteria

Exclusion criteria: The normal coronary patients The patients who are more than 75 years old The patients who are using Fibrate drugs in the same time The patients who are living in the villages and disable for follow up

Design outcomes

Primary

Measure	Time frame
Low density lipoprotein. Timepoint: At the start of study & 3 months later. Method of measurement: Blood test.;MDR1 (Multi-Drug Resistance ) gene polymorphism. Timepoint: At the start of study. Method of measurement: Polymerase Chain Reaction.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNafiseh Khalilzadeh

Sabzevar University of Medical Sciences

nafisekh31@yahoo.com+98 51 4466 4986

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026